| Trial ID: | L0470 |
| Source ID: | NCT01228903
|
| Associated Drug: |
Allopurinol
|
| Title: |
Uric Acid and the Endothelium in CKD
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01228903/results
|
| Conditions: |
Kidney Disease
|
| Interventions: |
DRUG: Allopurinol|OTHER: Placebo
|
| Outcome Measures: |
Primary: Change in Endothelial Dependent Dilation From Baseline to Week 12, Change in Endothelial Dependent Dilation measured by Flow Mediated Dilation at baseline and week 12, Baseline and 12 weeks | Secondary: Change in C-reactive Protein From Baseline to Week 12, Baseline and 12 weeks|Change in Serum Interleukin-6 From Baseline to Week 12, Baseline and 12 weeks|Change in Monocyte Chemotactic Protein-1 From Baseline to Week 12, Baseline and 12 weeks|Change in Oxidized Low Density Lipoprotein From Baseline to Week 12, Baseline and 12 weeks | Other: Change in Serum Uric Acid Levels From Baseline to Week 12, Serum uric acid levels were measured both at baseline and after 12 weeks, Baseline and 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: University of Colorado, Denver | Collaborators: National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
80
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2010-10
|
| Completion Date: |
2016-09
|
| Results First Posted: |
2017-02-23
|
| Last Update Posted: |
2017-06-28
|
| Locations: |
University of Colorado at Denver, Aurora, Colorado, 80045, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01228903
|
